Transarterial embolization with hepatectomy for ruptured hepatocellular carcinoma: a meta-analysis. Issue 5 (1st June 2022)

• Record Type: Journal Article
• Authors: Zhang, Feng-Qin; Li, Lin; Huang, Ping-Chao; Fu, Yu-Fei; Xu, Qing-Song
• Is Part Of: Minimally invasive therapy & allied technologies. Volume 31:Issue 5(2022)
• Page Start: 676
• Page End: 683
• Publication Date: 2022-06-01
• Subjects: Hepatectomy -- hepatocellular carcinoma -- rupture -- transarterial embolization; Endoscopy -- Periodicals; Interventional radiology -- Periodicals; Endoscopic surgery -- Periodicals; 617.05
• DOI: 10.1080/13645706.2021.1986724
• Languages: English
• ISSNs: 1364-5706

Abstract

Abstract: Purpose: To compare the clinical effectiveness between transarterial embolization (TAE) with staged hepatectomy (SH) and emergency hepatectomy (EH) for ruptured hepatocellular carcinoma (HCC). Material and methods: Pubmed, Embase, and Cochrane Library databases were screened for eligible publications from the inception of the databases till February 2021. Results: This meta-analysis included seven studies comprising 162 patients who underwent TAE with SH and 266 patients who underwent EH. The pooled intraoperative blood loss was less in the TAE with SH cohort, as compared to the EH cohort without significant difference ( p = .20). The pooled blood transfer rate ( p <.00001), blood transfer volume ( p = .002), and 30-day patient death ( p = .04) were all markedly reduced in the TAE with SH cohort versus the EH cohort. No significant differences in surgery duration ( p = .27), hospital stay period ( p = .81), complication rate ( p = 0.92), disease-free survival (DFS) ( p = .79), and overall survival (OS) ( p = 0.28) were found between the two groups. Conclusions: Compared with EH for ruptured HCC, TAE with SH could effectively decrease intraoperative blood loss and 30-day mortality. However, the long-term DFS and OS might not be beneficial to preoperative TAE.